World's Best Scientists 2026 revealed!
Suzanne M. Garland

Suzanne M. Garland

Award Badge
Microbiology
Australia
2026

D-Index & Metrics

Microbiology

D-Index
102
Citations
49021
World Ranking
362
National Ranking
8

Medicine

D-Index
102
Citations
51203
World Ranking
7534
National Ranking
224

Research.com Recognitions

  • 2026 - Research.com Microbiology in Australia Leader Award
  • 2025 - Research.com Microbiology in Australia Leader Award
  • 2023 - Research.com Microbiology in Australia Leader Award
  • 2022 - Research.com Microbiology in Australia Leader Award

Overview

Suzanne M. Garland is affiliated with the University of Melbourne in Australia. Their research work primarily spans the field of Medicine, with a strong focus on Epidemiology, Microbiology, Surgery, Oncology, and Hematology as key subfields.

Their main topics of study include Cervical Cancer and HPV Research, Reproductive Tract Infections Research, Genital Health and Disease, Hepatitis B Virus Studies, Blood Groups and Transfusion, Colorectal and Anal Carcinomas, and Microbial Infections and Disease Research.

Frequent publication venues for their work include:

  • SSRN Electronic Journal
  • Clinical Infectious Diseases
  • Vaccine
  • Journal of Medical Microbiology
  • The Journal of Infectious Diseases

They have collaborated often with the following co-authors:

  • Gerald L. Murray
  • Dorothy A. Machalek
  • Christopher K. Fairley
  • Catriona S. Bradshaw
  • Jennifer Danielewski

Recent publications of Suzanne M. Garland include:

  • "Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis," 2020, The Lancet Infectious Diseases
  • "The Natural History of Anal High-grade Squamous Intraepithelial Lesions in Gay and Bisexual Men," 2020, Clinical Infectious Diseases
  • "Human Papillomavirus Vaccination After COVID-19," 2021, JNCI Cancer Spectrum
  • "Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study," 2021, The Lancet Infectious Diseases
  • "Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review," 2022, Expert Review of Vaccines

The scope of their work indicates a comprehensive engagement with infectious diseases, vaccine research, and cancer epidemiology, especially relating to human papillomavirus and associated conditions.

Best Publications

  • Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

    Silvia de Sanjose;Wim G.V. Quint;Laia Alemany;Daan T. Geraets

  • Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

    Suzanne M. Garland;Suzanne M. Garland;Mauricio Hernandez-Avila;Cosette M. Wheeler;Gonzalo Perez

  • Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

    J. Paavonen;P. Naud;J. Salmeron;C. M. Wheeler

  • A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

    Elmar A. Joura;Anna R. Giuliano;Ole-Erik Iversen;Celine Bouchard

  • Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis

    Dorothy A Machalek;Mary Poynten;Fengyi Jin;Christopher K Fairley

  • High Recurrence Rates of Bacterial Vaginosis over the Course of 12 Months after Oral Metronidazole Therapy and Factors Associated with Recurrence

    Catriona S. Bradshaw;Anna N. Morton;Jane Hocking;Suzanne M. Garland

  • Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes : updated systematic review and meta-analysis

    Mélanie Drolet;Élodie Bénard;Norma Pérez;Marc Brisson;Marc Brisson

  • Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

    Matti Lehtinen;Jorma Paavonen;Cosette M. Wheeler;Unnop Jaisamrarn

  • A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines

    John T. Schiller;Xavier Castellsagué;Suzanne M. Garland

  • Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

    Elmar A Joura;Sepp Leodolter;Mauricio Hernandez-Avila;Cosette M Wheeler

  • Comprehensive control of human papillomavirus infections and related diseases.

    F. Xavier Bosch;Thomas R. Broker;David Forman;Anna Barbara Moscicki

  • Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

    Cosette M. Wheeler;Xavier Castellsagué;Suzanne M. Garland;Anne Szarewski

  • Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine

    Suzanne M. Garland;Marc Steben;Heather L. Sings;Margaret James

  • Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience

    Suzanne M. Garland;Susanne K. Kjaer;Nubia Muñoz;Stan L. Block

  • The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16–26 Years

    Darron R. Brown;Susanne K. Kjaer;Kristján Sigurdsson;Ole-Erik Iversen

  • Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

    Nubia Munoz;Susanne K. Kjaer;Kristján Sigurdsson;Ole Erik Iversen

  • Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

    Warner K. Huh;Elmar A. Joura;Anna R. Giuliano;Ole Erik Iversen;Ole Erik Iversen

  • Web-Based Recruiting for Health Research Using a Social Networking Site: An Exploratory Study

    Yeshe Fenner;Suzanne M Garland;Elya E Moore;Yasmin Jayasinghe

  • Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

    Elmar A. Joura;Suzanne M. Garland;Suzanne M. Garland;Jorma Paavonen;Daron Gale Ferris

  • A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

    Susanne K. Kjaer;Kristján Sigurdsson;Ole-Erik Iversen;Mauricio Hernandez-Avila

  • Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

    Joakim Dillner;Joakim Dillner;Susanne K. Kjaer;Cosette M. Wheeler;Kristján Sigurdsson

Frequent Co-Authors

Sepehr N. Tabrizi
Sepehr N. Tabrizi Royal Women's Hospital
Christopher K. Fairley
Christopher K. Fairley Monash University
Catriona S. Bradshaw
Catriona S. Bradshaw Monash University
John D. Wark
John D. Wark University of Melbourne
Andrew E. Grulich
Andrew E. Grulich University of New South Wales
Julia M.L. Brotherton
Julia M.L. Brotherton University of Melbourne
Jorma Paavonen
Jorma Paavonen University of Helsinki
Eric P F Chow
Eric P F Chow Monash University
Cosette M. Wheeler
Cosette M. Wheeler University of New Mexico
John M. Kaldor
John M. Kaldor University of New South Wales

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens doors to various healthcare and science-related career paths. For those interested in the administrative side of healthcare, pursuing a certified professional coder certification can be a valuable step. This certification prepares graduates to work efficiently with medical coding and billing, a crucial component of healthcare data management.

Another promising field linked to microbiology is health information management, which combines healthcare knowledge with data organization and technology. Entry-level professionals can explore roles with competitive salaries, as outlined in the health information management salary entry-level resources.

For students seeking formal education online, programs accredited by the Commission on Accreditation for Health Informatics and Information Management Education are essential. Finding the cahiim accredited health information management degree online ensures quality training and better career prospects.

Additionally, accelerated options such as an accelerated medical billing and coding certificate online can help professionals enter the workforce quickly while gaining relevant skills that complement microbiology knowledge in clinical settings.

Best Scientists Citing Suzanne M. Garland

Trending Scientists

Recently Published Articles